Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVE: Lysergic acid diethylamide (LSD) is used recreationally and in clinical research. The aim of the present study was to characterize the pharmacokinetics and exposure-response relationship of oral LSD. METHODS: We analyzed pharmacokinetic data from two published placebo-controlled, double-blind, cross-over studies using oral administration of LSD 100 and 200 µg in 24 and 16 subjects, respectively. The pharmacokinetics of the 100-µg dose is shown for the first time and data for the 200-µg dose were reanalyzed and included. Plasma concentrations of LSD, subjective effects, and vital signs were repeatedly assessed. Pharmacokinetic parameters were determined using compartmental modeling. Concentration-effect relationships were described using pharmacokinetic-pharmacodynamic modeling. RESULTS: Geometric mean (95% confidence interval) maximum plasma concentration values of 1.3 (1.2-1.9) and 3.1 (2.6-4.0) ng/mL were reached 1.4 and 1.5 h after administration of 100 and 200 µg LSD, respectively. The plasma half-life was 2.6 h (2.2-3.4 h). The subjective effects lasted (mean ± standard deviation) 8.2 ± 2.1 and 11.6 ± 1.7 h for the 100- and 200-µg LSD doses, respectively. Subjective peak effects were reached 2.8 and 2.5 h after administration of LSD 100 and 200 µg, respectively. A close relationship was observed between the LSD concentration and subjective response within subjects, with moderate counterclockwise hysteresis. Half-maximal effective concentration values were in the range of 1 ng/mL. No correlations were found between plasma LSD concentrations and the effects of LSD across subjects at or near maximum plasma concentration and within dose groups. CONCLUSIONS: The present pharmacokinetic data are important for the evaluation of clinical study findings (e.g., functional magnetic resonance imaging studies) and the interpretation of LSD intoxication. Oral LSD presented dose-proportional pharmacokinetics and first-order elimination up to 12 h. The effects of LSD were related to changes in plasma concentrations over time, with no evidence of acute tolerance. TRIAL REGISTRATION: NCT02308969, NCT01878942.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LSD (1, 100 µg) attained a maximal plasma concentration of 4 nM at two hours after oral administration in healthy volunteers, and declined thereafter with an approximately four hour half-life [99].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [99]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The subjective effects, both good and bad, closely tracked the plasma concentrations, as did physiological responses, such as heart rate and blood pressure increases.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“The pharmacokinetics of oral LSD (1) (100 and 200 µg) in human subjects indicated a mean plasma half-life of 2–6 h and a persistently close relationship between the individual LSD (1) concentration in plasma and the magnitude of subjective response within subjects, with moderate counterclockwise hysteresis during the 12 h after dosing [99].”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine
Sheiner, L. B., Stanski, D. R., Vozeh, S., Miller, R. D., & Ham, J. (1979) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1979253358 · Cited by 1,134
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859 · cited 7×
“Magnetic resonance imaging scanning correctly started at approximately 70 and 150 min in the studies that used intravenous [13] and oral (unpublished data from Study 1, 100 lg) routes of LSD administration, respectively, coinciding with the maximal response to LSD.”
InfluentialGasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750 · cited 2×
“The 200-lg dose preparation of LSD has been used in patients [5, 6], and the present phase I study provides the pharmacokinetic data for these phase II studies.”
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Increased global functional connectivity correlates with LSD-induced ego dissolution
Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., Laufs, H., Leech, R., McGonigle, J., Crossley, N., et al. (2016) · Current Biology · doi:10.1016/j.cub.2016.02.010 · Cited by 503 · cited 1×
“In contrast, no data are currently available on the plasma concentrations of LSD after intravenous administration of 75 lg of LSD base in saline [11], despite the publication of extensive pharmacodynamic data using this preparation and route of administration [10–19].”
Gasser, P., Kirchner, K., & Passie, T. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114555249 · Cited by 456 · cited 1×
“The 200-lg dose preparation of LSD has been used in patients [5, 6], and the present phase I study provides the pharmacokinetic data for these phase II studies.”
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455 · cited 2×
“Both doses were within the range of doses that are taken for recreational purposes [1].”
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 411 · cited 1×
“The LSD-induced subjective and autonomic effects were determined as a difference from placebo in the same subject at the corresponding time point to control for circadian changes and placebo effects [22].”
Self-citationReceptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379 · cited 1×
“, serotonin 5-HT2A receptor stimulation [35]), such as dimetyltryptamine or psilocybin, also produced subjective and autonomic effects almost instantaneously and peak effects within 2–5 min after intravenous administration [36–38].”
Self-citationLSD enhances suggestibility in healthy volunteers
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3714-z · Cited by 320
LSD‐induced entropic brain activity predicts subsequent personality change
Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. (2016) · Human Brain Mapping · doi:10.1002/hbm.23234 · Cited by 303 · cited 2×
“Recent studies have reported the effects of LSD on various neuronal correlates of brain activation [12, 13, 16, 17].”
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293 · cited 1×
“The intravenous 75-lg dose of LSD produced comparably strong alterations in consciousness to the 100-lg dose in the present study [10, 31].”
LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality
Dolder, P. C., Schmid, Y., Müller, F., Borgwardt, S., & Liechti, M. E. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.82 · Cited by 247 · cited 4×
“The corresponding peak effect data and dose-response statistics have been previously reported [21].”
InfluentialSelf-citationLSD enhances the emotional response to music
Kaelen, M., Barrett, F. S., Roseman, L., Lorenz, R., Family, N., Bolstridge, M., Curran, H. V., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4014-y · Cited by 201
Alterations of consciousness and mystical-type experiences after acute LSD in humans
Liechti, M. E., Dolder, P. C., & Schmid, Y. (2017) · Psychopharmacology · doi:10.1007/s00213-016-4453-0 · Cited by 198 · cited 1×
“The intravenous 75-lg dose of LSD produced comparably strong alterations in consciousness to the 100-lg dose in the present study [10, 31].”
Self-citationHysek, C. M., Simmler, L. D., Ineichen, M., Grouzmann, E., Hoener, M. C., Brenneisen, R., Huwyler, J., & Liechti, M. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.78 · Cited by 152 · cited 1×
“No clockwise hysteresis was found for any of the pharmacodynamic outcome measures, and thus no evidence was found of acute tolerance as described for other psychoactive substances, such as methylenedioxymethamphetamine [39] or cocaine [40], or for repeated administration of LSD [41].”
Self-citationLSD modulates music-induced imagery via changes in parahippocampal connectivity
Kaelen, M., Roseman, L., Kahan, J., Ribeiro, A., Orbán, C., Lorenz, R., Barrett, F. S., Bolstridge, M., Williams, T., Williams, L., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.018 · Cited by 149 · cited 2×
“Recent studies have reported the effects of LSD on various neuronal correlates of brain activation [12, 13, 16, 17].”
Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects
Strajhar, P., Schmid, Y., Liakoni, E., Dolder, P. C., Rentsch, K. M., Kratschmar, D. V., Odermatt, A., & Liechti, M. E. (2016) · Journal of Neuroendocrinology · doi:10.1111/jne.12374 · Cited by 129
Self-citationBelleville, R. E., Fraser, H. F., Isbell, H., LOGAN, C. R., & Wikler, A. (1956) · PubMed · Cited by 126
Over 30 million psychedelic users in the United States
Krebs, T. S., & Johansen, P.-Ø. (2013) · F1000Research · doi:10.12688/f1000research.2-98.v1 · Cited by 124 · cited 1×
“Lysergic acid diethylamide continues to be used for recreational and personal purposes [3].”
Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
Baumeister, D., Barnes, G., Giaroli, G., & Tracy, D. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314527985 · Cited by 121
Speth, J., Speth, C., Kaelen, M., Schloerscheidt, A. M., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116628430 · Cited by 118
Persistence of lysergic acid diethylamide in the plasma of human subjects
Aghajanian, G. K., & Bing, O. H. L. (1964) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196455611 · Cited by 117 · cited 2×
“9 h after intravenous administration of 2 lg/kg of LSD [24] but shorter than the 3.”
Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans
Dolder, P. C., Schmid, Y., Haschke, M., Rentsch, K. M., & Liechti, M. E. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv072 · Cited by 112 · cited 7×
“pharmacokinetics and concentration–effect relationship for the 200-lg dose of LSD [23] were reanalyzed and included for comparison with the 100-lg dose.”
InfluentialSelf-citationISBELL, H. (1956) · A.M.A. Archives of Neurology & Psychiatry · doi:10.1001/archneurpsyc.1956.02330290012002 · Cited by 111 · cited 1×
“No clockwise hysteresis was found for any of the pharmacodynamic outcome measures, and thus no evidence was found of acute tolerance as described for other psychoactive substances, such as methylenedioxymethamphetamine [39] or cocaine [40], or for repeated administration of LSD [41].”
Hysek, C. M., & Liechti, M. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2761-6 · Cited by 63
Self-citationWagner, J. G., Aghajanian, G. K., & Bing, O. H. L. (1968) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196895635 · Cited by 62
Roseman, L., Sereno, M. I., Leech, R., Kaelen, M., Orban, C., McGonigle, J., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. (2016) · Human Brain Mapping · doi:10.1002/hbm.23224 · Cited by 59 · cited 2×
“Recent studies have reported the effects of LSD on various neuronal correlates of brain activation [12, 13, 16, 17].”
THE EFFECTS OF D‐LYSERGIC ACID DIETHYLAMIDE ON CEREBRAL CIRCULATION AND OVER‐ALL METABOLISM
Sokoloff, L., Perlin, S., Kornetsky, C. H., & Kety, S. S. (1957) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1957.tb40742.x · Cited by 58
Martin, R., Schürenkamp, J., Gasse, A., Pfeiffer, H., & Köhler, H. (2012) · International Journal of Legal Medicine · doi:10.1007/s00414-012-0796-1 · Cited by 53
Carhart-Harris, R. L., Williams, T. M., Sessa, B., Tyacke, R. J., Rich, A. S., Feilding, A., & Nutt, D. J. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110367445 · Cited by 52
Gallimore, A. R., & Strassman, R. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00211 · Cited by 52
Intranasal Cocaine: Dose Relationships of Psychological Effects and Plasma Levels
Dyke, C. V., Ungerer, J. C., Jatlow, P. I., Barash, P. G., & Byck, R. (1983) · The International Journal of Psychiatry in Medicine · doi:10.2190/5x0n-twkj-ggy6-t10n · Cited by 45 · cited 1×
“No clockwise hysteresis was found for any of the pharmacodynamic outcome measures, and thus no evidence was found of acute tolerance as described for other psychoactive substances, such as methylenedioxymethamphetamine [39] or cocaine [40], or for repeated administration of LSD [41].”
A placebo-controlled investigation of synaesthesia-like experiences under LSD
Terhune, D. B., Luke, D. P., Kaelen, M., Bolstridge, M., Feilding, A., Nutt, D., Carhart-Harris, R., & Ward, J. (2016) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2016.04.005 · Cited by 45
Dolder, P. C., Liechti, M. E., & Rentsch, K. (2014) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-014-8388-1 · Cited by 44 · cited 3×
“Samples were thawed for the first time for both analyses, this was also the case for study 2 (200 lg) because separate sets of samples were stored and used for the present [28] and previous [29] analyses.”
MethodSelf-citationThe determination of LSD in human plasma following oral administration
Upshall, D. G., & Wailling, D. G. (1972) · Clinica Chimica Acta · doi:10.1016/0009-8981(72)90159-3 · Cited by 43 · cited 1×
“5–5 h but because of sparse and short sampling could not derive pharmacokinetic parameters [25].”
Steuer, A. E., Poetzsch, M., Stock, L., Eisenbeiss, L., Schmid, Y., Liechti, M. E., & Kraemer, T. (2017) · Drug Testing and Analysis · doi:10.1002/dta.2042 · Cited by 41 · cited 2×
“Samples were thawed for the first time for both analyses, this was also the case for study 2 (200 lg) because separate sets of samples were stored and used for the present [28] and previous [29] analyses.”
MethodSelf-citationKlette, K. L., Horn, C. K., Stout, P. R., & Anderson, C. J. (2002) · Journal of Analytical Toxicology · doi:10.1093/jat/26.4.193 · Cited by 40
Kupferschmidt, K. (2014) · Science · doi:10.1126/science.345.6192.18 · Cited by 19
Psychedelic and nonpsychedelic LSD and psilocybin for cluster headache
Davenport, W. J. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.1150082 · Cited by 16
Research works printed but not linked: 1
- Hoch PH Studies in routes of administration and counteracting drugs: lysergic acid diethylmide and mescaline in experimental psychosis 1956 New York Grune and Stratton
Cited by
Andersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269
Effects of psilocybin therapy on personality structure
Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart‐Harris, R. L. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12904 · Cited by 267
“Intriguingly, the treatment effect in these trials appears to last for several months – much longer than the pharmacological presence of the actual compounds (25, 26).”
BackgroundDistinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0569-3 · Cited by 247
Self-citationHolze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., Duthaler, U., Varghese, N., Eckert, A., Borgwardt, S., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00883-6 · Cited by 245
Self-citation
Metadata
- Authors
- Dolder, P. C., Schmid, Y., Steuer, A. E., Kraemer, T., Rentsch, K. M., Hammann, F., & Liechti, M. E.
- Affiliations
- University Hospital of Basel (CH)
- University of Zurich (CH)
- Corresponding author
- Liechti, Matthias E.
- ORCID
- Venue
- Clinical Pharmacokinetics
- Published
- 2017-02-14
- Volume
- 56
- Issue
- 10
- Pages
- 1219-1230
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC5591798
- OpenAlex
- W2589071607
- Cited by
- 133
- References
- 42
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 14 · 2023: 19 · 2022: 23 · 2021: 20 · 2020: 14 · 2019: 9 · 2018: 7 · 2017: 4
- FWCI
- 11.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- edoc (University of Basel) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_170249)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Keywords
- lysergic acid diethylamide, LSD, pharmacokinetics, pharmacodynamics, oral administration, exposure-response relationship, subjective effects, plasma concentration, dose proportionality, first-order elimination, acute tolerance, psychedelics, hysteresis, vital signs, healthy volunteers, compartmental modeling, pharmacokinetic-pharmacodynamic modeling
- MeSH terms
- Administration, Oral, Adult, Affect, Blood Pressure, Dose-Response Relationship, Drug, Double-Blind Method, Female, Half-Life, Hallucinogens, Heart Rate, Humans, Lysergic Acid Diethylamide, Male, Middle Aged, Cross-Over Studies, Young Adult, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.